China Oncology ›› 2019, Vol. 29 ›› Issue (8): 568-575.doi: 10.19401/j.cnki.1007-3639.2019.08.002

Previous Articles     Next Articles

The toxicity of chimeric antigen receptor T-cell immunotherapy in B-cell lymphoma: a Meta-analysis

KANG Xun 1 , ZHANG Xiyou 2 , CHEN Feng 1 , LI Dandan 2 , DONG Qianqian 2 , SONG Qingkun 2 , ZHONG Xiaosong 2 , LI Wenbin 1   

  1. 1. Department of General Nervous Cancer Therapy, Beijing Tiantan Hospital, Capital Medical University, Beijing 100050, China; 2. Department of Brain Glioma, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China
  • Online:2019-08-30 Published:2019-09-29
  • Contact: LI Wenbin E-mail: liwenbin@ccmu.com

Abstract: Background and purpose: For patients with relapsed or refractory B-cell lymphoma, conventional therapy is not effective. Researching new treatment technology to improve prognosis is imminent. Chimeric antigen receptor T-cell (CAR-T) technology has high safety and remission rate in B-cell lymphoma. The incidence rates of cytokine release syndrome (CRS) and neurological toxicity in the treatment of B-cell lymphoma with CAR-T were investigated in this study, so as to provide guidance for CAR-T in the treatment of lymphoma. Methods: Following comprehensive retrieval of PubMed database and the Cochrane Library database in English literature, a quantitative and comprehensive analysis was conducted for ten articles regarding CAR-T in the treatment of B-cell lymphoma that were published from the establishment of the databases to Jan, 2018. The incidence rate was used as the outcome. According to the difference of toxicity, Meta-analysis of the incidence rate was performed. Results: The total incidence rate of CRS in B-cell lymphoma treated with CAR-T was 57% (95% CI: 0.25-0.90), while the total incidence rate of neurological toxicity in B-cell lymphoma treated with CAR-T was 48% (95% CI: 0.30-0.66). Conclusion: The incidence rates of CRS and neurological toxicity in B-cell lymphoma treated with CAR-T are both high.

Key words: Lymphoma, B-cell, Toxicity, Meta-analysis, Chimeric antigen receptor T-cell, Incidence rate